AXT to distribute stem cell solutions from StemBioSys
Scientific equipment supplier AXT has further enhanced its cellular research product portfolio through the addition of stem cell solutions from StemBioSys, signing an agreement to distribute to the latter’s products to researchers in Australia and New Zealand.
StemBioSys is a US-based company that specialises in producing human-derived stem cell products. With a range of human cell lines and derived matrices, the company’s products are used to mimic the in vivo physiological conditions during in vitro cell culture. StemBioSys currently carries two broad product ranges: CELLvo Matrix and CELLvo cells.
CELLvo Matrix is a commercially available substrate that aims to recapitulate biochemical as well as structural and mechanical cues of the native niche by leaving the extracellular matrix intact. Completely cell derived, the matrix creates a biologically relevant culture environment in vitro for a variety of cell types by providing all the cues cells expect to receive in vivo. For researchers, this means that the response of cells to experimental variables can be directly assessed, eliminating complicating effects induced by standard in vitro culture conditions.
CELLvo cells meanwhile maintain a far more natural phenotype compared with standard derived cells, according to the companies, and are cultured and isolated using the physiologically relevant CELLvo Matrix technology. A range of cell types are currently offered that are early passage and have xeno-free versions where possible. All cells are sourced from young, healthy tissue and have never seen plastic, ensuring high quality.
“Australia and New Zealand are leading areas in cell research, and we are delighted to have the opportunity to gain meaningful access to this market though our partnership with AXT,” said StemBioSys President and CEO Bob Hutchens. “AXT is a recognised life science tool company with deep technical expertise. AXT carries a full range of complementary products and we are very excited to announce them as our new distributor in these markets. We believe that this will be a great partnership for AXT, StemBioSys and for researchers in Australia and New Zealand.”
AXT Managing Director Richard Trett added, “Stem cell research is a key area of development that holds great potential for many areas such as genetics and drug development. We are excited to be able to extend our range of tools that can assist with their groundbreaking work.”
Agilent Technologies has signed a definitive agreement to acquire the privately owned BioTek...
The partnership fuses IDT's oligo synthesis with 3CR's PACE Genotyping Master Mix and...
Western Australia will play a key role in the Australian Space Agency's efforts to triple the...